Product news from the 01/02/07 news brief

Share this article:
The FDA has approved Janssen’s Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia. The once-daily oral medication is specifically designed to deliver paliperidone -- the active ingredient derived from risperidone -- through the innovative OROS(R) extended-release technology, demonstrating powerful efficacy and a proven safety and tolerability profile. The FDA approved BioForm Medical’s Radiesse, a cosmetic dermal filler for the long-lasting correction of moderate to severe facial wrinkles and folds. Radiesse also received FDA approval for the correction of facial fat loss in patients with HIV.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.